We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Abnova and Ardic Instruments Collaborate on Fiber-Optic Protein Quantification System

By LabMedica International staff writers
Posted on 13 Jul 2011
Abnova Corporation (Taipei City, Taiwan), a biotech company specializing in high throughput monoclonal antibody production, and Ardic Instruments (Taipei City, Taiwan), provider of analytical instruments for nanotechnology, unveiled their new label-free protein detection platform. More...
Based on a new fiber-optic particle, plasmon resonance (FO-PPR) system, this new protein platform enables the development of a variety of applications ranging from protein quantification to protein-protein/protein-small molecule interactions to kinetic measurements.

Most significantly, the FO-PPR technology meets an unmet need for higher sensitivity, protein quantification using a stand-alone, capturing antibody in contrast to the conventional platform currently used, which requires both capturing and detection antibody for protein detection. The Abnova and Ardic collaboration harnesses their expertise in reagent manufacturing and instrument engineering providing an integrated solution for label-free protein-quantification markets.

“We are very excited to have the opportunity to collaborate with Ardic to introduce an unprecedented label-free system for the biotech industry,” said Dr. Wilber Huang, president and CEO of Abnova.

“As an instrument developer, we are eager to work with an antibody reagent manufacturer like Abnova,” stated Dr. Jerome Shen, president and CEO of Ardic Instruments. “Being a pioneer in this new field of FO-PPR, we are keen to have the largest possible applications available to the customers to capture a greater market share in today’s competitive landscape.”

Related Links:

Abnova
Ardic Instruments



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.